Defined Terms Contract Clauses (16,805)

Defined Terms. In addition to the terms defined elsewhere in this Note, the following terms shall have the following meanings when used in this Note. All capitalized terms used in this Note and not otherwise defined shall have the meanings ascribed thereto in the Credit Agreement. A. "Default" shall mean when used in reference to this Note or any other document, or in reference to any provision or obligation under this Note or any other document, the occurrence of an event or the existence of a condition... which, with the passage of time or the giving of notice, or both, would constitute an Event of Default under this Note or such other document, as the case may be. B. "Default Rate" shall be as defined in Section 6 hereof. C. "Event of Default" shall mean (i) when used in reference to this Note, one or more of the events or occurrences referred to in Section 10.A. of this Note; and (ii) when used in reference to any other document, a default or event of default under such document that has continued after the giving of any applicable notice and the expiration of any applicable grace or cure periods. View More

Defined Terms. Terms not otherwise defined herein shall have the meaning ascribed to them in the License Agreement. 1 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 2. Amendments to the License Agreement. (a)The following technologies are hereby added to Revised Schedule A (Patent Rights) to the Exosomes License Agreement: (i) [***] (ii) [***] (iii) [***] (iv) [***] (v) [***] (vi) [***]... (vii) [***] (b)No later than thirty (30) days after the Fourth Amendment Date, Licensee shall reimburse CSMC for all of the costs, including attorneys' fees, actually incurred by CSMC, before and after the Fourth Amendment Date, in the preparation and/or prosecution of the patent applications referenced in Section 2(a) hereof, which, as of the Fourth Amendment Date, amount to a total of $49,950.78. All amounts paid by Licensee to CSMC under this Section shall be nonrefundable. (c)The parties agree that Milestone 4 on Schedule D to the Agreement is hereby modified as follows: "On or before December 31, 2018, Licensee shall file an Investigational New Drug (IND) application for at least one (1) Product." 3. Extracellular Vesicles. The parties acknowledge that the International Society for Extracellular Vesicles defines the term "extracellular vesicles" as including exosomes, microvesicles, microparticles, ectosomes, oncosomes and prostasomes. View More

Defined Terms. All capitalized terms in this Amendment not otherwise defined herein shall have the meaning ascribed to such terms in the Fee Allocation Agreement. Unless otherwise specified, all section references in this Amendment refer to sections of the Fee Allocation Agreement.

Defined Terms. Unless otherwise defined herein, all capitalized terms used herein shall have the meanings ascribed to them in the SLA.